Phase II trial of pyrazoloacridine (NSC#366140) in patients with metastatic breast cancer

Bhuvaneswari Ramaswamy, Ewa Mrozek, John Philip Kuebler, Tanios Bekaii-Saab, Eric H. Kraut

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Purpose: Pyrazoloacridine (PZA) is an investigational nucleic acid binding agent that inhibits the activity of topoisomerases 1 and 2. We conducted a phase II clinical study to determine the efficacy and toxicities of PZA in patients with metastatic breast cancer (MBC). Experimental Design: In this phase II multicenter study, patients who were treated with no more than one prior chemotherapy for MBC were treated with 750 mg/m2 of PZA given as a 3 hour intravenous infusion every 3 weeks. Treatment cycles were continued until disease progression or unacceptable toxicities. The study was designed to distinguish between a response rate of <15% vs >30% (alpha=0.10, beta=0.10) using Simons optimal 2-stage design. At least 2 responses were required in the first 12 patients in the 1st stage and 6 of 35 in the 2nd stage to recommend the agent for further study. Results: Two patients in the first stage had a response allowing accrual to second stage. A total of 15 patients (out of 35 planned) were treated on the study prior to premature closure. Three patients had a partial response (20%) lasting 4.5-6 months. Two patients had stable disease for 3 and 5 months. The dose limiting toxicity was granulocytopenia with ten patients requiring dose reduction or dose delay for grade 4 neutropenia. Other grade 3 and 4 toxicities include vomiting (n=2), nausea (n=2), neurotoxicity (n=1), fatigue (n=1), anemia (n=1), dyspnea 9n=1) and renal (n=1). Conclusions: Pyrazoloacridine demonstrated modest activity in patients with metastatic breast cancer.

Original languageEnglish (US)
Pages (from-to)347-351
Number of pages5
JournalInvestigational New Drugs
Volume29
Issue number2
DOIs
StatePublished - Apr 1 2011
Externally publishedYes

Fingerprint

NSC 366140
Breast Neoplasms
Agranulocytosis
Neutropenia
Intravenous Infusions

Keywords

  • Metastatic breast cancer
  • Phase II
  • Pyrazoloacridine

ASJC Scopus subject areas

  • Oncology
  • Pharmacology
  • Pharmacology (medical)

Cite this

Phase II trial of pyrazoloacridine (NSC#366140) in patients with metastatic breast cancer. / Ramaswamy, Bhuvaneswari; Mrozek, Ewa; Kuebler, John Philip; Bekaii-Saab, Tanios; Kraut, Eric H.

In: Investigational New Drugs, Vol. 29, No. 2, 01.04.2011, p. 347-351.

Research output: Contribution to journalArticle

Ramaswamy, Bhuvaneswari ; Mrozek, Ewa ; Kuebler, John Philip ; Bekaii-Saab, Tanios ; Kraut, Eric H. / Phase II trial of pyrazoloacridine (NSC#366140) in patients with metastatic breast cancer. In: Investigational New Drugs. 2011 ; Vol. 29, No. 2. pp. 347-351.
@article{16b35f5e799d4283ba35e8c699e257ea,
title = "Phase II trial of pyrazoloacridine (NSC#366140) in patients with metastatic breast cancer",
abstract = "Purpose: Pyrazoloacridine (PZA) is an investigational nucleic acid binding agent that inhibits the activity of topoisomerases 1 and 2. We conducted a phase II clinical study to determine the efficacy and toxicities of PZA in patients with metastatic breast cancer (MBC). Experimental Design: In this phase II multicenter study, patients who were treated with no more than one prior chemotherapy for MBC were treated with 750 mg/m2 of PZA given as a 3 hour intravenous infusion every 3 weeks. Treatment cycles were continued until disease progression or unacceptable toxicities. The study was designed to distinguish between a response rate of <15{\%} vs >30{\%} (alpha=0.10, beta=0.10) using Simons optimal 2-stage design. At least 2 responses were required in the first 12 patients in the 1st stage and 6 of 35 in the 2nd stage to recommend the agent for further study. Results: Two patients in the first stage had a response allowing accrual to second stage. A total of 15 patients (out of 35 planned) were treated on the study prior to premature closure. Three patients had a partial response (20{\%}) lasting 4.5-6 months. Two patients had stable disease for 3 and 5 months. The dose limiting toxicity was granulocytopenia with ten patients requiring dose reduction or dose delay for grade 4 neutropenia. Other grade 3 and 4 toxicities include vomiting (n=2), nausea (n=2), neurotoxicity (n=1), fatigue (n=1), anemia (n=1), dyspnea 9n=1) and renal (n=1). Conclusions: Pyrazoloacridine demonstrated modest activity in patients with metastatic breast cancer.",
keywords = "Metastatic breast cancer, Phase II, Pyrazoloacridine",
author = "Bhuvaneswari Ramaswamy and Ewa Mrozek and Kuebler, {John Philip} and Tanios Bekaii-Saab and Kraut, {Eric H.}",
year = "2011",
month = "4",
day = "1",
doi = "10.1007/s10637-009-9338-1",
language = "English (US)",
volume = "29",
pages = "347--351",
journal = "Investigational New Drugs",
issn = "0167-6997",
publisher = "Kluwer Academic Publishers",
number = "2",

}

TY - JOUR

T1 - Phase II trial of pyrazoloacridine (NSC#366140) in patients with metastatic breast cancer

AU - Ramaswamy, Bhuvaneswari

AU - Mrozek, Ewa

AU - Kuebler, John Philip

AU - Bekaii-Saab, Tanios

AU - Kraut, Eric H.

PY - 2011/4/1

Y1 - 2011/4/1

N2 - Purpose: Pyrazoloacridine (PZA) is an investigational nucleic acid binding agent that inhibits the activity of topoisomerases 1 and 2. We conducted a phase II clinical study to determine the efficacy and toxicities of PZA in patients with metastatic breast cancer (MBC). Experimental Design: In this phase II multicenter study, patients who were treated with no more than one prior chemotherapy for MBC were treated with 750 mg/m2 of PZA given as a 3 hour intravenous infusion every 3 weeks. Treatment cycles were continued until disease progression or unacceptable toxicities. The study was designed to distinguish between a response rate of <15% vs >30% (alpha=0.10, beta=0.10) using Simons optimal 2-stage design. At least 2 responses were required in the first 12 patients in the 1st stage and 6 of 35 in the 2nd stage to recommend the agent for further study. Results: Two patients in the first stage had a response allowing accrual to second stage. A total of 15 patients (out of 35 planned) were treated on the study prior to premature closure. Three patients had a partial response (20%) lasting 4.5-6 months. Two patients had stable disease for 3 and 5 months. The dose limiting toxicity was granulocytopenia with ten patients requiring dose reduction or dose delay for grade 4 neutropenia. Other grade 3 and 4 toxicities include vomiting (n=2), nausea (n=2), neurotoxicity (n=1), fatigue (n=1), anemia (n=1), dyspnea 9n=1) and renal (n=1). Conclusions: Pyrazoloacridine demonstrated modest activity in patients with metastatic breast cancer.

AB - Purpose: Pyrazoloacridine (PZA) is an investigational nucleic acid binding agent that inhibits the activity of topoisomerases 1 and 2. We conducted a phase II clinical study to determine the efficacy and toxicities of PZA in patients with metastatic breast cancer (MBC). Experimental Design: In this phase II multicenter study, patients who were treated with no more than one prior chemotherapy for MBC were treated with 750 mg/m2 of PZA given as a 3 hour intravenous infusion every 3 weeks. Treatment cycles were continued until disease progression or unacceptable toxicities. The study was designed to distinguish between a response rate of <15% vs >30% (alpha=0.10, beta=0.10) using Simons optimal 2-stage design. At least 2 responses were required in the first 12 patients in the 1st stage and 6 of 35 in the 2nd stage to recommend the agent for further study. Results: Two patients in the first stage had a response allowing accrual to second stage. A total of 15 patients (out of 35 planned) were treated on the study prior to premature closure. Three patients had a partial response (20%) lasting 4.5-6 months. Two patients had stable disease for 3 and 5 months. The dose limiting toxicity was granulocytopenia with ten patients requiring dose reduction or dose delay for grade 4 neutropenia. Other grade 3 and 4 toxicities include vomiting (n=2), nausea (n=2), neurotoxicity (n=1), fatigue (n=1), anemia (n=1), dyspnea 9n=1) and renal (n=1). Conclusions: Pyrazoloacridine demonstrated modest activity in patients with metastatic breast cancer.

KW - Metastatic breast cancer

KW - Phase II

KW - Pyrazoloacridine

UR - http://www.scopus.com/inward/record.url?scp=79957464991&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79957464991&partnerID=8YFLogxK

U2 - 10.1007/s10637-009-9338-1

DO - 10.1007/s10637-009-9338-1

M3 - Article

C2 - 19844661

AN - SCOPUS:79957464991

VL - 29

SP - 347

EP - 351

JO - Investigational New Drugs

JF - Investigational New Drugs

SN - 0167-6997

IS - 2

ER -